The contribution of B cells in the pathophysiology of JIA-U+ is supported by the observation that anti-CD20 monoclonal antibody therapy (Rituximab) is effective in treating patients with (severe) JIA associated uveitis (12, 13). The gene discussed is MS4A1; the disease is uveitis.